Journal Article

DKFZ-2026-00039

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapy

Frapolli, R. ; Meroni, M. ; Bello, E. ; Pirona, L. ; Callegari, E. ; Kebede, V. ; Pellerani, I. ; Canesi, S. ; Scanziani, E. ; Dirksen, U.DKFZ* ; Angelico, P. ; Biondi, S. ; Malinverno, M.

2026
Elsevier St. Louis

Abstract: Ewing sarcoma is a rare and aggressive cancer of the bone and soft tissues primarily affecting children andyoung adults. Prognosis for patients with metastatic or recurrent disease remains poor despite intensivemultimodal therapy, highlighting the need of novel therapeutic approaches. The disialoganglioside GD2 ishighly expressed on Ewing sarcoma cells, making this tumor eligible for anti-GD2 immunotherapy with dinutuximab beta. Through in vitro and in vivo approaches, this study demonstrated that dinutuximab beta effectively suppressed tumor growth by 60% (p = 0.0135) and improved survival rate by 68% (p = 0.0006) in amouse model xenograft. The combination therapy with doxorubicin demonstrated superior efficacycompared to monotherapy, with enhanced tumor suppression (86%; p = 0.0009) and an extension of survivalrate (146%; p = 0.000025). This study showed that dinutuximab beta, particularly in combination with standard chemotherapy, offers a promising approach to improve outcomes for high-risk Ewing sarcoma patients,providing a more effective alternative to current treatments.

Note: #DKTKZFB9# / #NCTZFB9#

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)
2. Koordinierungsstelle NCT West (WT01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---